In order to explore new treatment modalities for cancer, it is impor tant to identify qualitative or quantitative differences in metabolic pro cesses between normal and malignant cells.
INTRODUCTION
In order to design new anticancer agents or to develop new treatment modalities for cancer it is important to identify and take advantage of qualitative or quantitative differences in met abolic processes between normal and malignant cells. Previous studies have provided evidence that some malignant cells pos sess elevated receptor-mediated uptake of LDL3 (see Ref. l for review). LDL is the major cholesterol-carrying lipoprotein in human plasma, containing two thirds of plasma cholesterol (2). Each LDL particle contains approximately 1500 molecules of cholesteryl ester surrounded by a polar shell of phospholipids, free cholesterol, and apolipoprotein-B. Cells can fulfill their cholesterol requirements by receptor-mediated uptake of LDL from plasma and/or endogenous synthesis of cholesterol (2) . Once bound to its cell surface receptor, LDL is internalized and degraded in lysosomes, and the subsequently released choles terol may be used for membrane synthesis, steroid hormone production, or bile acid production in the various tissues.
It has been shown that freshly isolated leukemic cells from patients with acute myelogenous leukemia have elevated LDL receptor activities, compared to normal WBC and nucleated bone marrow cells (3, 4) . Hypocholesterolemia is a frequent finding in patients with acute leukemia (5, 6) and cholesterol levels are inversely correlated with the LDL receptor activities of the leukemic cells (5) . This suggests that the mechanism behind the hypocholesterolemia is high LDL catabolism by the leukemic cells (5) . In vitro catabolism of LDL can be deter mined from the cellular degradation of I25I-labeled LDL (3, 4) . This labeling technique is, however, not suitable for determina tion of in vivo catabolism of LDL since the radioactive degra dation fragments are rapidly released by the cells into the blood and excreted by the kidneys. Using [14C]sucrose-labeled LDL, we have recently demonstrated that the uptake of LDL by leu kemic cells is elevated in leukemic patients in vivo (7) . This labeling technique is suitable for in vivo studies of LDL cata bolism since the [14C]sucrose moiety is retained in lysosomes following cellular uptake (8) .
Hypocholesterolemia is also associated with nonhematolog ical malignancies like lung cancer (9, 10) . Previous studies have shown elevated LDL receptor activity in gynecological cancer cells in tissue culture, compared to the corresponding normal cells (11) , and high LDL uptake in experimental animal tumor models in vivo (12) (13) (14) . Until now, there has been no demon stration of high uptake by solid tumors in vivo in humans. In the present study, therefore, we investigated the in vivo accumula tion of radiolabeled LDL in human lung cancer tissue after i.v. injection before surgery. We employed the same labeling tech nique with [14C]sucrose-LDL as used in the previous study in patients with leukemia (7) . If the uptake of LDL is similarly elevated in lung cancer tissue, this would suggest that selective chemotherapy could be achieved by administering cytotoxic drugs incorporated in LDL particles.
MATERIALS AND METHODS
Patients. Clinical characteristics of the patients are given in Table 1 . The study was approved by the Ethics Committee at the Karolinska Hospital. Informed consent was obtained from each subject entering the study.
Materials. [U-l4C]Sucrose (specific activity, >5550 GBq/mmol) was purchased from Amersham and cyanuric chloride was purchased from Sigma. Other materials were from previously reported sources (7) .
Lipoproteins. LDL (density, 1.020-1.063 g/ml) was isolated from serum of healthy blood donors by sequential ultracentrifugation (15) .
[l4C]Sucrose-LDL (specific activity, 5-19 cpm/ng of protein) was pre pared as described by Pittman et al. (16) . The purity of LDL prepara tions was checked by agarose gel electrophoresis. Autoradiography af ter agarose gel electrophoresis of [l4C]sucrose-LDL showed that all radioactivity was present in a single band with mobility similar to that of native LDL. The preparations of [l4C]sucrose-labeled LDL were filtered through a Millipore 0.22-^m HA filter under aseptic conditions and were stored at 4Â°Cfor <3 weeks. Immediately before the i.v. injec tion, the preparation was refiltered.
In were taken from the tumor, avoiding macroscopically necrotic material, and from surrounding lung tissue. The specimens were collected in ice-cold 0.15 M NaCl solution, rinsed extensively, and cut into 2-8 pieces of about 200-400 mg, which were treated with 500 >i\ of 2 M NaOH by incubation at 60Â°Cfor 2-4 h. The solubili/ed tissue samples were neutralized with 5 MHCI and the pH was stabilized by the addition of l M Tris-HCI, pH 7.4, as described previously (7). Finally, the I4C radioactivity was determined in a Packard liquid scintillation counter with appropriate quench correction, after the addition of 10 ml of Picofluor 15. It was verified that an increase in the amount of counted material gave rise to a linear increase in the radioactivity. The results were expressed as the sum of the radioactivities of the pieces divided by the total weight of the tissue assayed. The radioactivity in plasma was determined by the direct addition of 500 n\ of plasma to 10 ml of Picofluor 15 and subsequent counting.
Histopathological Examination. The primary histopathological di agnoses of the lung tumors were confirmed upon reexamination of the original histolÃ³gica! slides, which had been prepared from the surgical material. The proportion of tumor cells in individual tumors was also determined (Table 1) .
Other Assays. Plasma total cholesterol, LDL cholesterol, and trig lycÃ©ride concentrations were determined using enzymatic techniques (Merck, Darmstadt, Germany). The protein concentrations of LDL preparations were determined by the method of Lowry et al. (17) . with bovine serum albumin as a standard.
Statistical Analysis. Significance levels were derived from Student's t test for paired observations.
RESULTS
No side effects were seen following the administration of [14C]sucrose-LDL i.v. to the patients with different lung tu mors. Plasma radioactivity decay curves for 9 of the 10 patients are presented in Fig. 1 . After injection, plasma radioactivity declined in a bimodal fashion, with terminal half-lives in the range of 35-50 h.
The uptake of [l4C]sucrose-LDL in tumor tissue and sur rounding lung tissue has been plotted in Fig. 2 . All but one patient (patient 8) had a primary lung cancer. Patient 8 had four mÃ©tastasesof a chordoma which showed a low uptake of radio activity, compared with surrounding tissue. In 7 of the 9 pa tients with primary lung cancer, the uptake in tumor tissue was higher (range, 1.5-3.0-fold) than in surrounding tissue. Con- sidering all patients, the mean LDL uptake (expressed as LDL protein) was 150.4 Â±66.6 ng/g (mean Â±SD) for normal tissue and 251.8 Â±146.8 ng/g for tumor tissue (P =0.011 ). Patient 1, a 44-year-old male with a large cell undifferentiated carcinoma, had a tumor uptake approximately 3 times the uptake of sur rounding tissue. In patient 3, a 70-year-old male with a poorly differentiated squamous cell carcinoma, the uptake was approx imately 2.5 times higher in the tumor, compared with the sur rounding tissue. In contrast, in patient 5, with a poorly differ entiated squamous cell carcinoma, and in patient 7, with a poorly differentiated mixed squamous cell carcinoma and ade nocarcinoma, the uptake in tumor and surrounding tissue was very similar.
Patients 2 and 9 had large tumor burdens. Patient 2 had a poorly differentiated adenocarcinoma with metastasis to the lung and regional lymph nodes and patient 9 had a poorly 6245 (Table 1) . Bars, SD. differentiated mixed squamous cell carcinoma and adenocarcinoma with pleural and thoracic wall infiltration. Interestingly, both these patients had the most rapid preoperative decay of plasma radioactivity.
Tumor tissue exhibited a more heterogeneous uptake of radioactivity, compared to normal lung tissue. The mean coef ficient of variation for the 2-8 pieces into which the tumor biopsies were subdivided was 31.6% (range, 1.6-54.6%), com pared with normal lung tissue in which 2-5 pieces had a mean coefficient of variation of 19.1% (range, 1.9-48.2%).
DISCUSSION
The present study demonstrates that lung cancer tissue has a higher /;/ vivo assimilation of LDL than does surrounding lung tissue. Recently, Henriksson et al. (18) demonstrated in prostatic cancer patients that the plasma clearance of LDL was more rapid in patients with mÃ©tastases,compared to patients without mÃ©tastases,indicating that an increased tumor burden increases the elimination of LDL from blood. Several investi gators have also demonstrated high LDL uptake by solid tu mors in vivo in animals (12) (13) (14) .
EpidemiolÃ³gica! studies have also given indirect support for high LDL uptake by cancer tissue, from the inverse correlation found between cancer mortality and serum cholesterol concen tration (19, 20) . Few studies have been performed on choles terol or lipoprotein levels in patients with newly diagnosed lung cancer. Chao et al. (9) made serial measurements of cholesterol levels in lung cancer patients and found that in several patients cholesterol levels declined rapidly during the course of the dis ease. This was seen in patients with either adenocarcinomas or squamous cell carcinomas. Alexopoulos et al. (21) measured cholesterol and lipoprotein levels in 103 cancer patients. Can cer patients as a group had significantly lower total cholesterol and LDL cholesterol levels, compared with control patients. In 31 patients with lung cancer the mean total cholesterol and LDL cholesterol levels were not significantly different, com pared with controls. On the other hand, a significantly lower mean value of pre-0-lipoproteins (very low density lipoproteins) was found among the lung cancer patients, compared with con trols. In the present study we also determined cholesterol levels, but the cholesterol levels were not remarkably low and none of the patients exhibited a marked hypocholesterolemia. Of par ticular interest is the rapid preoperative disappearance of ra dioactivity from blood of the patients (patients 2 and 9) with advanced tumors with high LDL uptake. In contrast, patients 5 and 8, with small tumors and low uptake of radioactivity, ex hibited slow preoperative clearances of radioactivity.
What then is the mechanism for the elevated tumor uptake of LDL? As estimated from the uptake of ' "[-labeled LDL and cyclohexanedione-modified '-"I-labeled LDL, which is not rec ognized by the LDL receptor, Hynds et al. (12) reported that the receptor-mediated uptake of LDL by a virus-induced par otid adenoma in mice was very high. When expressed per gram of tissue, it was surpassed only by uptake in the adrenals (12) . With the same technique. Norata et al. (13) found that the receptor-mediated uptake of LDL by a transplantable fibrosar coma tumor in mice was much higher than that in liver, spleen, and muscle. However, they also found evidence for increased nonspecific uptake of LDL by the tumor. Lombardi et al. (14) found that several experimental tumors in mice had a higher relative uptake of LDL, compared to the liver, and that the in vivo uptake correlated well with in vitro specific binding of l2SI-/3-very low density lipoproteins to tumor membranes. Fur ther support for high receptor-mediated uptake of LDL by tu mor cells as a mechanism for LDL assimilation by tumor cells can be found in studies with patients with acute leukemia who were given i.v. injections of [l4C]sucrose-LDL (7). A strong correlation was found between the in vivo uptake of [14C]sucrose-LDL by leukemic cells and the in vitro rate of receptormediated degradation of 125I-LDL by the isolated leukemic cells. Rudling et al. (22) determined LDL receptor densities in crude tissue homogenates of normal and malignant human tissues obtained at surgery, using a binding assay based on the ability of heparin to specifically release receptor-bound LDL. They found that the adrenal gland and the ovary had the highest receptor densities and that, in certain cases, tumors from the stomach and parotid gland expressed very high LDL binding.
The reason for elevated LDL receptor activity in certain ma lignant cells is not known and can only be speculated upon. The findings of low cholesterol content (3, (23) (24) (25) and high levels of endogenous cholesterol synthesis (3, 26, 27) in acute myelogenous leukemia cells indicate that the enhanced cellular uptake of cholesterol is a compensatory response to mechanisms that lower the cholesterol content of the cell. Increased cholesterol demand for membrane synthesis in rapidly proliferating cells is one possibility. Indeed, LDL receptor activity in cultured cells is very much dependent on the growth rate (28) . Another pos sibility is that tumor cells need more cholesterol because of rapid membrane turnover. A defect in the regulation of the LDL receptor in tumor cells could be another explanation for the elevated receptor activity. However, Ho et al. (3) showed that LDL receptors in leukemic cells are subject to regulation by LDL similar to that in normal cells.
The largest difference in LDL uptake between normal and malignant tissues in the present study was about 3-fold. It can be argued that such a difference is not enough if LDL is to be considered as a targeting vehicle for cytotoxic agents. However, we observed that in most cases the biopsies from normal lung tissue macroscopically appeared to contain more blood than the tumor specimens, which could mean that the difference between tumor and normal lung was underestimated, especially when account is taken of the fact that surgery was performed 1-3 days after injection of radiolabeled LDL and blood radioactivity was still considerable at surgery. Even if the true difference in LDL uptake between nomai cells and cancer cells is at most 2-3-fold, this could have a major impact on the outcome of LDL-mediated chemotherapy and could lead to an increased therapeutic index and cure of the patient.
Previous studies have shown that cytotoxic agents can be incorporated into LDL and delivered to tumor cells both in vitro and in vivo (29) . The organs most likely to suffer from the cytotoxic effects of drug-LDL complexes are those with a high LDL uptake, such as the adrenals and the liver. As indicated by animal studies, it may be possible to circumvent this problem by pretreatment with steroids and bile acids (12) . Further in vivo studies of LDL uptake in different human solid tumors are needed in order to better characterize and understand choles terol turnover in normal and malignant tissue.
In conclusion, we have shown that lung cancer tissue in vivo assimilates more LDL than does surrounding normal lung tis sue. Hence, LDL should be considered as a potentially inter esting drug carrier for treatment of lung cancer.
